Year: 2025

  • UPDATE: Cancer Programme IPP-204106

    ImmuPharma plc (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist drug discovery and development company is pleased to provide an update on its lead cancer programme IPP-204106. As announced in September last year the Company commenced dosing in cancer patients with the next generation of the “polyplexed Nucant” (See notes to editors). Three…

  • FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities

    ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is delighted to announce that following its discussions with the FDA (the US Food & Drug Administration), it has been granted an updated SPA (Special Protocol Assessment) for Lupuzor. Under the new SPA, the necessary number of patients…

  • Appointment of Scientific Advisory Board

    ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is delighted to announce that it has appointed some of the world’s most eminent physicians to provide scientific advice and support for Lupuzor’s pivotal phase III programme. The Five Scientific Adisory Board members are: Dr. Daniel J. Wallace,…

  • ImmuPharma secures £50M financing facility for Lupuzor Phase III

    Facility Underwritten by Henderson Global’s Subsidary Darwin Strategic ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is pleased to announce that it has secured a £50 million, five year Equity Financing Facility (“EFF”) with Darwin Strategic Limited (“Darwin”), a majority owned subsidiary of Henderson Global Investors’…

  • Immupharma gets Lupuzor research boost

    Immupharma’s (LON:IMM) new lupus treatment Lupuzor has the potential to offer substantial benefits to patients compared with current market leader Benlysta, new research has suggested. A survey of US and European rheumatologists carried out by Decision Research indicated emerging therapies such as Lupuzor had the potential to improve on IV belimumab (Human Genome Sciences/GlaxoSmithKline’s Benlysta)…

  • ImmuPharma Commences Trading on the Stuttgart Stock Exchange

    ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announces that it has been informed by Baader Bank AG that its shares are now being traded on the third segment  of the Stuttgart Stock Exchange. Baader Bank AG has experience and expertise for trading in German…

  • CNRS Confirms Lupuzor’sTM Effectiveness

    ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that its key scientific collaboration partner and the inventor of ImmuPharma’s lead compound, LupuzorTM has issued a press release confirming the effectiveness of the LupuzorTM peptide P140. LupuzorTM is ImmuPharma’s lead compound and potential blockbuster drug…

  • ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C.

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to today outline the key abstract information presented on Wednesday 14 November at the 2012 Annual American College of Rheumatology (“ACR”) Meeting which was held this week. The ACR Annual Scientific Meeting is the premier worldwide scientific meeting devoted…

  • ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C.

    ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the 2012 Annual American College of Rheumatology (“ACR”) Meeting  which is being held between 11 – 14 of November. ImmuPharma will be presenting on Wednesday 14 November 2012. The ACR…

  • Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing

    ImmuPharma plc (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is pleased to announce that its cancer programme IPP-204106 has begun further clinical trials with the next generation of “polyplexed Nucant”. The first patients have started dosing in this new Phase I/ II clinical trial. This “polyplexed Nucant”…